HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology

Context ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA....

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2017-02, Vol.35 (4), p.446-464
Hauptverfasser:	Bartley, Angela N, Washington, Mary Kay, Colasacco, Carol, Ventura, Christina B, Ismaila, Nofisat, Benson, 3rd, Al B, Carrato, Alfredo, Gulley, Margaret L, Jain, Dhanpat, Kakar, Sanjay, Mackay, Helen J, Streutker, Catherine, Tang, Laura, Troxell, Megan, Ajani, Jaffer A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - enzymology Adenocarcinoma - pathology Algorithms Biomarkers, Tumor - analysis Esophageal Neoplasms - enzymology Esophageal Neoplasms - pathology Esophagogastric Junction - enzymology Esophagogastric Junction - pathology Humans Receptor, ErbB-2 - analysis Stomach Neoplasms - enzymology Stomach Neoplasms - pathology Systematic Reviews as Topic
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!